I 

110TH CONGRESS 

2D SESSION H. R. 5629 

To amend the Public Health Service Act to establish a pathway for the 

licensure of biosimilar biological products, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 13, 2008 

Ms. ESHOO (for herself, Mr. BARTON of Texas, Mr. HILL, Mr. UPTON, Mr. 

WYNN, Mr. PITTS, Ms. ZOE LOFGREN of California, Mr. ROGERS of 

Michigan, Mr. CAPUANO, Mr. BUYER, Mr. MCGOVERN, Mr. TIM MURPHY

of Pennsylvania, Mr. LYNCH, and Mr. FERGUSON) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period 

to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee 

concerned 

A BILL 

To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, 

and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Pathway for 

5 Biosimilars Act’’. 


rwilkins on PROD1PC63 with BILLS
2 

•HR 5629 IH

1 SEC. 2. TABLE OF CONTENTS. 

2 The table of contents for this Act is as follows: 

Sec. 1. Short title. 

Sec. 2. Table of contents. 

TITLE I—AMENDMENTS TO PUBLIC HEALTH SERVICE ACT 

Sec. 101. Approval pathway for biosimilar biological products. 

Sec. 102. Fees relating to biosimilar biological products. 

TITLE II—AMENDMENTS TO PATENT ACT 

Sec. 201. Amendments to certain patent provisions. 

3 TITLE I—AMENDMENTS TO 

4 PUBLIC HEALTH SERVICE ACT 

5 SEC. 101. LICENSURE PATHWAY FOR BIOSIMILAR BIOLOGI6 CAL PRODUCTS. 

7 (a) LICENSURE OF BIOLOGICAL PRODUCTS AS BIO8 SIMILAR OR INTERCHANGEABLE.—Section 351 of the 

9 Public Health Service Act (42 U.S.C. 262) is amended— 

10 (1) in subsection (a)(1)(A), by inserting ‘‘under 

11 this subsection or subsection (k)’’ after ‘‘biologics li12 cense’’; and 

13 (2) by adding at the end the following: 

14 ‘‘(k) LICENSURE OF BIOLOGICAL PRODUCTS AS BIO15 SIMILAR.— 

16 ‘‘(1) IN GENERAL.—Any person may submit an 

17 application for licensure of a biological product 

18 under this subsection. 

19 ‘‘(2) CONTENT.— 


rwilkins on PROD1PC63 with BILLS
3 

•HR 5629 IH

1 ‘‘(A) REQUIRED INFORMATION.—An appli2 cation submitted under this subsection shall in3 clude information demonstrating that— 

4 ‘‘(i) the biological product is bio5 similar to a reference product based upon 

6 data derived from— 

7 ‘‘(I) analytical studies that dem8 onstrate that the biological product is 

9 highly similar to the reference product 

10 notwithstanding minor differences in 

11 clinically inactive components; 

12 ‘‘(II) animal studies (including 

13 the assessment of toxicity); and 

14 ‘‘(III) a clinical study or studies 

15 (including, but not limited to, the as16 sessment of immunogenicity and phar17 macokinetics or pharmacodynamics) 

18 that are sufficient to demonstrate 

19 safety, purity, and potency for each 

20 condition of use for which the ref21 erence product is approved; 

22 ‘‘(ii) the biological product and ref23 erence product utilize the same mechanism 

24 or mechanisms of action for the condition 

25 or conditions of use prescribed, recVerDate Aug 31 2005 23:13 Mar 14, 2008 Jkt 069200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H5629.IH H5629

rwilkins on PROD1PC63 with BILLS
4 

•HR 5629 IH

1 ommended, or suggested in the proposed 

2 labeling, but only to the extent the mecha3 nism or mechanisms of action are known 

4 for the reference product; 

5 ‘‘(iii) the condition or conditions of 

6 use prescribed, recommended, or suggested 

7 in the labeling proposed for the biological 

8 product have been previously approved for 

9 the reference product; 

10 ‘‘(iv) the route of administration, the 

11 dosage form, and the strength of the bio12 logical product are the same as those of 

13 the reference product; and 

14 ‘‘(v) the facility in which the biological 

15 product is manufactured, processed, 

16 packed, or held meets standards designed 

17 to assure that the biological product con18 tinues to be safe, pure, and potent. 

19 ‘‘(B) WAIVER REGARDING ANALYTICAL

20 STUDIES, ANIMAL STUDIES, AND CLINICAL

21 STUDIES.— 

22 ‘‘(i) IN GENERAL.—The Secretary 

23 may, in the Secretary’s discretion, deter24 mine that an element described in sub25 clause (I), (II), or (III) of subparagraph 


rwilkins on PROD1PC63 with BILLS
5 

•HR 5629 IH

1 (A)(i) is unnecessary and waive the re2 quirement that such element be submitted 

3 in an application under this subsection. 

4 ‘‘(ii) ASSESSMENTS OF

5 IMMUNOGENICITY.—Notwithstanding 

6 clause (i), the Secretary may determine 

7 that an assessment of immunogenity de8 scribed in subparagraph (A)(i)(III) is un9 necessary and waive the requirement that 

10 such an assessment be submitted in an ap11 plication under this subsection only if the 

12 Secretary has published a final guidance, 

13 following receipt and consideration of pub14 lic comments on a draft guidance— 

15 ‘‘(I) advising that it is feasible in 

16 the current state of scientific knowl17 edge to make determinations on 

18 immunogenicity with respect to prod19 ucts in the product class to which the 

20 biological product belongs; and 

21 ‘‘(II) explaining the data that 

22 will be required to support such a de23 termination. 

24 ‘‘(C) ADDITIONAL INFORMATION.—An ap25 plication submitted under this subsection— 


rwilkins on PROD1PC63 with BILLS
6 

•HR 5629 IH

1 ‘‘(i) shall include publicly-available in2 formation regarding the Secretary’s pre3 vious determination that the reference 

4 product is safe, pure, and potent; and 

5 ‘‘(ii) may include any additional infor6 mation in support of the application, in7 cluding publicly-available information with 

8 respect to the reference product or another 

9 biological product. 

10 ‘‘(3) EVALUATION BY SECRETARY.—Upon re11 view of an application (or a supplement to an appli12 cation) submitted under this subsection, the Sec13 retary shall approve the application (or the supple14 ment) if— 

15 ‘‘(A) the Secretary determines that the in16 formation submitted in the application (or the 

17 supplement) is sufficient to show that the bio18 logical product is biosimilar to the reference 

19 product with respect to each condition of use 

20 for which the reference product is approved; 

21 and 

22 ‘‘(B) the applicant (or other appropriate 

23 person) consents to the inspection of the facility 

24 that is the subject of the application, in accord25 ance with subsection (c). 


rwilkins on PROD1PC63 with BILLS
7 

•HR 5629 IH

1 ‘‘(4) SAFETY STANDARDS FOR DETERMINING

2 INTERCHANGEABILITY.— 

3 ‘‘(A) DETERMINATION.—Upon review of 

4 an application submitted under this subsection 

5 or any supplement to such application, the Sec6 retary shall determine the biological product to 

7 be interchangeable with the reference product if 

8 the Secretary determines that the information 

9 submitted in the application (or a supplement 

10 to such application) is sufficient to show that— 

11 ‘‘(i) the biological product— 

12 ‘‘(I) is biosimilar to the reference 

13 product and any biological product li14 censed under this subsection that has 

15 been determined to be interchangeable 

16 with the reference product; and 

17 ‘‘(II) can be expected to produce 

18 the same clinical result as the ref19 erence product in any given patient 

20 for each condition of use prescribed, 

21 recommended, or suggested in the la22 beling of the reference product; and 

23 ‘‘(ii) for a biological product that is 

24 administered more than once to an indi25 vidual, the risk in terms of safety or diminVerDate Aug 31 2005 23:13 Mar 14, 2008 Jkt 069200 PO 00000 Frm 00007 Fmt 6652 Sfmt 6201 E:\BILLS\H5629.IH H5629

rwilkins on PROD1PC63 with BILLS
8 

•HR 5629 IH

1 ished efficacy of alternating or switching 

2 between use of the biological product and 

3 the reference product is not greater than 

4 the risk of using the reference product 

5 without such alternation or switch. 

6 ‘‘(B) GUIDELINES.—Notwithstanding sub7 paragraph (A), the Secretary may not make a 

8 determination that a biological product licensed 

9 under this subsection is interchangeable with 

10 the reference product unless the Secretary has 

11 published a final guidance, following receipt and 

12 consideration of public comments on a draft 

13 guidance— 

14 ‘‘(i) advising that it is feasible in the 

15 current state of scientific knowledge to 

16 make such determinations with respect to 

17 products in the product class to which that 

18 biological product belongs; and 

19 ‘‘(ii) explaining the data that will be 

20 required to support such a determination. 

21 ‘‘(5) GENERAL RULES.— 

22 ‘‘(A) ONE REFERENCE PRODUCT PER AP23 PLICATION.—A biological product, in an appli24 cation submitted under this subsection, may not 


rwilkins on PROD1PC63 with BILLS
9 

•HR 5629 IH

1 be evaluated against more than 1 reference 

2 product. 

3 ‘‘(B) REVIEW.—An application submitted 

4 under this subsection shall be reviewed by the 

5 division within the Food and Drug Administra6 tion that is responsible for the review and ap7 proval of the application under which the ref8 erence product is licensed. 

9 ‘‘(C) RISK EVALUATION AND MITIGATION

10 STRATEGIES.—The authority of the Secretary 

11 with respect to risk evaluation and mitigation 

12 strategies under the Federal Food, Drug, and 

13 Cosmetic Act shall apply to biological products 

14 licensed under this subsection in the same man15 ner as such authority applies to biological prod16 ucts licensed under subsection (a). 

17 ‘‘(D) LISTED SELECT AGENTS AND TOX18 INS.—If information in an application sub19 mitted under this subsection, in a supplement 

20 to such an application, or otherwise available to 

21 the Secretary shows that a biological product is, 

22 bears, or contains a select agent or toxin listed 

23 in section 73.3 or 73.4 of title 42, section 121.3 

24 or 121.4 of title 9, or section 331.3 of title 7 

25 of the Code of Federal Regulations (or any sucVerDate Aug 31 2005 23:13 Mar 14, 2008 Jkt 069200 PO 00000 Frm 00009 Fmt 6652 Sfmt 6201 E:\BILLS\H5629.IH H5629

rwilkins on PROD1PC63 with BILLS
10 

•HR 5629 IH

1 cessor regulations), the Secretary shall not li2 cense the biological product under this sub3 section. 

4 ‘‘(6) EXCLUSIVITY FOR FIRST INTERCHANGE5 ABLE BIOLOGICAL PRODUCT.—The Secretary shall 

6 not make a determination under paragraph (4) that 

7 a second or subsequent biological product is inter8 changeable with the same reference product for 

9 which a prior biological product has received a deter10 mination of interchangeability until 24 months after 

11 the later of— 

12 ‘‘(A) the date of the first commercial mar13 keting of the first biosimilar biological product 

14 determined to be interchangeable for that ref15 erence product; or 

16 ‘‘(B) with respect to a product marketed 

17 before the date the product is determined to be 

18 interchangeable, the date that the product is 

19 determined to be interchangeable. 

20 ‘‘(7) EXCLUSIVITY FOR REFERENCE PROD21 UCT.— 

22 ‘‘(A) EFFECTIVE DATE OF BIOSIMILAR AP23 PLICATION LICENSURE.—Subject to subpara24 graph (D) and paragraph (8), approval of an 

25 application under this subsection may not be 


rwilkins on PROD1PC63 with BILLS
11 

•HR 5629 IH

1 made effective by the Secretary until the date 

2 that is 12 years after the date on which the ref3 erence product was first licensed under sub4 section (a). 

5 ‘‘(B) FILING PERIOD.—An application 

6 under this subsection may not be submitted to 

7 the Secretary until the later of— 

8 ‘‘(i) the date of commencement of a 

9 proceeding for issuance of guidance pursu10 ant to paragraph (9) with respect to the 

11 product class within which the product 

12 that is the subject of such application falls; 

13 or 

14 ‘‘(ii) the date that is 4 years after the 

15 date on which the reference product was 

16 first licensed under subsection (a). 

17 ‘‘(C) FIRST LICENSURE.—For purposes of 

18 this paragraph, the date on which the reference 

19 product was first licensed under subsection (a) 

20 does not include the date of approval of a sup21 plement or of a subsequent application for a 

22 new indication, route of administration, dosage 

23 form, or strength for the previously licensed ref24 erence product. 


rwilkins on PROD1PC63 with BILLS
12 

•HR 5629 IH

1 ‘‘(D) MEDICALLY SIGNIFICANT NEW INDI2 CATION.—If, during the 8-year period following 

3 licensure of the reference product, the Secretary 

4 approves a supplement to the application for 

5 the reference product that seeks approval to 

6 market the reference product for a new indica7 tion that, if approved, would be a significant 

8 improvement, compared to marketed products, 

9 in the treatment, diagnosis, or prevention of 

10 disease, approval of an application submitted 

11 under this subsection may not be made effective 

12 by the Secretary until the date that is 14 years 

13 after the date on which the reference product 

14 was first licensed under subsection (a). 

15 ‘‘(8) PEDIATRIC STUDIES.— 

16 ‘‘(A) EXCLUSIVITY.—If, before or after li17 censure of the reference product under sub18 section (a) of this section, the Secretary deter19 mines that information relating to the use of 

20 such product in the pediatric population may 

21 produce health benefits in that population, the 

22 Secretary makes a written request for pediatric 

23 studies (which shall include a timeframe for 

24 completing such studies), the applicant or hold25 er of the approved application agrees to the reVerDate Aug 31 2005 23:13 Mar 14, 2008 Jkt 069200 PO 00000 Frm 00012 Fmt 6652 Sfmt 6201 E:\BILLS\H5629.IH H5629

rwilkins on PROD1PC63 with BILLS
13 

•HR 5629 IH

1 quest, such studies are completed using appro2 priate formulations for each age group for 

3 which the study is requested within any such 

4 timeframe, and the reports thereof are sub5 mitted and accepted in accordance with section 

6 505A(d)(3) of the Federal Food, Drug, and 

7 Cosmetic Act— 

8 ‘‘(i) the period referred to in para9 graph (7)(A) of this subsection is deemed 

10 to be 12 years and 6 months rather than 

11 12 years; and 

12 ‘‘(ii) if paragraph (7)(D) of this sub13 section applies, the period referred to in 

14 such paragraph is deemed to be 14 years 

15 and 6 months rather than 14 years. 

16 ‘‘(B) EXCEPTION.—The Secretary shall 

17 not extend the period referred to in subpara18 graph (A)(i) or (A)(ii) of this paragraph if the 

19 determination under section 505A(d)(3) of the 

20 Federal Food, Drug, and Cosmetic Act is made 

21 later than 9 months prior to the expiration of 

22 such period. 

23 ‘‘(C) APPLICATION OF CERTAIN PROVI24 SIONS.—The provisions of subsections (a), (d), 

25 (e), (f), (h), (j), (k), and (l) of section 505A of 


rwilkins on PROD1PC63 with BILLS
14 

•HR 5629 IH

1 the Federal Food, Drug, and Cosmetic Act 

2 shall apply with respect to the extension of a 

3 period under subparagraph (A) of this para4 graph to the same extent and in the same man5 ner as such provisions apply with respect to the 

6 extension of a period under subsection (b) or 

7 (c) of section 505A of the Federal Food, Drug, 

8 and Cosmetic Act. 

9 ‘‘(9) GUIDANCE DOCUMENTS.— 

10 ‘‘(A) IN GENERAL.—The Secretary shall, 

11 after opportunity for public comment, issue 

12 final guidance with respect to the licensure 

13 under this subsection of a biological product or 

14 product class. Such guidance shall be issued in 

15 accordance, except as provided in subparagraph 

16 (B)(i), with section 701(h) of the Federal Food, 

17 Drug, and Cosmetic Act. 

18 ‘‘(B) PUBLIC COMMENT.— 

19 ‘‘(i) IN GENERAL.—Before issuing 

20 final guidance under subparagraph (A), 

21 the Secretary shall publish a proposed 

22 guidance, provide an opportunity for the 

23 public to comment on the proposed guid24 ance, and publish a response to comments 

25 received under this clause. 


rwilkins on PROD1PC63 with BILLS
15 

•HR 5629 IH

1 ‘‘(ii) INPUT REGARDING MOST VALU2 ABLE GUIDANCE.—The Secretary shall es3 tablish a process through which the public 

4 may provide the Secretary with input re5 garding priorities for issuing guidance. 

6 ‘‘(C) CERTAIN PRODUCT CLASSES.— 

7 ‘‘(i) GUIDANCE.—The Secretary may 

8 indicate in a guidance document under 

9 subparagraph (A) that the Secretary will 

10 not license a product or product class (not 

11 including any recombinant protein) under 

12 this subsection because the science and ex13 perience, as of the date of such guidance, 

14 does not allow such licensure. 

15 ‘‘(ii) MODIFICATION OR REVERSAL.— 

16 The Secretary may issue a subsequent 

17 guidance document under subparagraph 

18 (A) to modify or reverse a guidance docu19 ment under clause (i). 

20 ‘‘(D) PETITION FOR INITIATION OF GUID21 ANCE FOR CERTAIN PRODUCTS.—In the case of 

22 a reference product that was licensed by the 

23 Secretary more than 7 years prior to the date 

24 of the enactment of the Pathway for 

25 Biosimilars Act, a person may petition the SecVerDate Aug 31 2005 23:13 Mar 14, 2008 Jkt 069200 PO 00000 Frm 00015 Fmt 6652 Sfmt 6201 E:\BILLS\H5629.IH H5629

rwilkins on PROD1PC63 with BILLS
16 

•HR 5629 IH

1 retary at any time to commence the process for 

2 issuing final guidance under subparagraph (A) 

3 for the product class to which the reference 

4 product belongs. Any such petition shall include 

5 a description of the scientific feasibility and ra6 tionale for the request. For guidance petitioned 

7 under this subparagraph, the Secretary shall, 

8 within 2 years of such petition, issue final guid9 ance with respect to that product class. 

10 ‘‘(E) REQUIREMENT FOR APPLICATION

11 CONSIDERATION.—The Secretary may not ac12 cept an application under this subsection until 

13 the Secretary has initiated a proceeding for 

14 issuance of guidance with respect to the product 

15 class within which the product that is the sub16 ject of the application falls. The Secretary may 

17 not approve an application under this sub18 section until the Secretary has completed the 

19 proceeding for issuance of guidance with re20 spect to the product class within which the 

21 product that is the subject of the application 

22 falls. 

23 ‘‘(F) REQUIREMENT FOR PRODUCT CLASS24 SPECIFIC GUIDANCE.—Product class-specific 


rwilkins on PROD1PC63 with BILLS
17 

•HR 5629 IH

1 guidance issued under subparagraph (A) shall 

2 include a description of— 

3 ‘‘(i) the criteria that the Secretary will 

4 use to determine whether a biological prod5 uct is biosimilar to a reference product in 

6 such product class; 

7 ‘‘(ii) the criteria, if available, that the 

8 Secretary will use to determine whether a 

9 biological product meets the standards for 

10 interchangeability described in paragraph 

11 (4); and 

12 ‘‘(iii) the criteria, if available, that the 

13 Secretary will use to assess 

14 immunogenicity. 

15 ‘‘(10) NAMING.—The Secretary shall ensure 

16 that the labeling and packaging of each biological 

17 product licensed under this subsection bears a name 

18 that uniquely identifies the biological product and 

19 distinguishes it from the reference product and any 

20 other biological products licensed under this sub21 section following evaluation against such reference 

22 product. 

23 ‘‘(l) PATENT NOTICES; RELATIONSHIP TO FINAL AP24 PROVAL.— 


rwilkins on PROD1PC63 with BILLS
18 

•HR 5629 IH

1 ‘‘(1) DEFINITIONS.—For the purposes of this 

2 subsection, the term— 

3 ‘‘(A) ‘biosimilar product’ means the bio4 logical product that is the subject of the appli5 cation under subsection (k); 

6 ‘‘(B) ‘relevant patent’ means a patent 

7 that— 

8 ‘‘(i) expires after the date specified in 

9 subsection (k)(7)(A) that applies to the 

10 reference product; and 

11 ‘‘(ii) could reasonably be asserted 

12 against the applicant due to the unauthor13 ized making, use, sale, or offer for sale 

14 within the United States, or the importa15 tion into the United States of the bio16 similar product, or materials used in the 

17 manufacture of the biosimilar product, or 

18 due to a use of the biosimilar product in 

19 a method of treatment that is indicated in 

20 the application; 

21 ‘‘(C) ‘reference product sponsor’ means the 

22 holder of an approved application or license for 

23 the reference product; and 

24 ‘‘(D) ‘interested third party’ means a per25 son other than the reference product sponsor 


rwilkins on PROD1PC63 with BILLS
19 

•HR 5629 IH

1 that owns a relevant patent, or has the right to 

2 commence or participate in an action for in3 fringement of a relevant patent. 

4 ‘‘(2) HANDLING OF CONFIDENTIAL INFORMA5 TION.—Any entity receiving confidential information 

6 pursuant to this subsection shall designate one or 

7 more individuals to receive such information. Each 

8 individual so designated shall execute an agreement 

9 in accordance with regulations promulgated by the 

10 Secretary. The regulations shall require each such 

11 individual to take reasonable steps to maintain the 

12 confidentiality of information received pursuant to 

13 this subsection and use the information solely for 

14 purposes authorized by this subsection. The obliga15 tions imposed on an individual who has received con16 fidential information pursuant to this subsection 

17 shall continue until the individual returns or de18 stroys the confidential information, a court imposes 

19 a protective order that governs the use or handling 

20 of the confidential information, or the party pro21 viding the confidential information agrees to other 

22 terms or conditions regarding the handling or use of 

23 the confidential information. 

24 ‘‘(3) PUBLIC NOTICE BY SECRETARY.—Within 

25 30 days of acceptance by the Secretary of an appliVerDate Aug 31 2005 23:13 Mar 14, 2008 Jkt 069200 PO 00000 Frm 00019 Fmt 6652 Sfmt 6201 E:\BILLS\H5629.IH H5629

rwilkins on PROD1PC63 with BILLS
20 

•HR 5629 IH

1 cation filed under subsection (k), the Secretary shall 

2 publish a notice identifying— 

3 ‘‘(A) the reference product identified in the 

4 application; and 

5 ‘‘(B) the name and address of an agent 

6 designated by the applicant to receive notices 

7 pursuant to paragraph (4)(B). 

8 ‘‘(4) EXCHANGES CONCERNING PATENTS.— 

9 ‘‘(A) EXCHANGES WITH REFERENCE

10 PRODUCT SPONSOR.— 

11 ‘‘(i) Within 30 days of the date of ac12 ceptance of the application by the Sec13 retary, the applicant shall provide the ref14 erence product sponsor with a copy of the 

15 application and information concerning the 

16 biosimilar product and its production. This 

17 information shall include a detailed de18 scription of the biosimilar product, its 

19 method of manufacture, and the materials 

20 used in the manufacture of the product. 

21 ‘‘(ii) Within 60 days of the date of re22 ceipt of the information required to be pro23 vided under clause (i), the reference prod24 uct sponsor shall provide to the applicant 

25 a list of relevant patents owned by the refVerDate Aug 31 2005 23:13 Mar 14, 2008 Jkt 069200 PO 00000 Frm 00020 Fmt 6652 Sfmt 6201 E:\BILLS\H5629.IH H5629

rwilkins on PROD1PC63 with BILLS
21 

•HR 5629 IH

1 erence product sponsor, or in respect of 

2 which the reference product sponsor has 

3 the right to commence an action of in4 fringement or otherwise has an interest in 

5 the patent as such patent concerns the bio6 similar product. 

7 ‘‘(iii) If the reference product sponsor 

8 is issued or acquires an interest in a rel9 evant patent after the date on which the 

10 reference product sponsor provides the list 

11 required by clause (ii) to the applicant, the 

12 reference product sponsor shall identify 

13 that patent to the applicant within 30 days 

14 of the date of issue of the patent, or the 

15 date of acquisition of the interest in the 

16 patent, as applicable. 

17 ‘‘(B) EXCHANGES WITH INTERESTED

18 THIRD PARTIES.— 

19 ‘‘(i) At any time after the date on 

20 which the Secretary publishes a notice for 

21 an application under paragraph (3), any 

22 interested third party may provide notice 

23 to the designated agent of the applicant 

24 that the interested third party owns or has 

25 rights under 1 or more patents that may 


rwilkins on PROD1PC63 with BILLS
22 

•HR 5629 IH

1 be relevant patents. The notice shall iden2 tify at least 1 patent and shall designate 

3 an individual who has executed an agree4 ment in accordance with paragraph (2) to 

5 receive confidential information from the 

6 applicant. 

7 ‘‘(ii) Within 30 days of the date of re8 ceiving notice pursuant to clause (i), the 

9 applicant shall send to the individual des10 ignated by the interested third party the 

11 information specified in subparagraph 

12 (A)(i), unless the applicant and interested 

13 third party otherwise agree. 

14 ‘‘(iii) Within 90 days of the date of 

15 receiving information pursuant to clause 

16 (ii), the interested third party shall provide 

17 to the applicant a list of relevant patents 

18 which the interested third party owns, or 

19 in respect of which the interested third 

20 party has the right to commence or partici21 pate in an action for infringement. 

22 ‘‘(iv) If the interested third party is 

23 issued or acquires an interest in a relevant 

24 patent after the date on which the inter25 ested third party provides the list required 


rwilkins on PROD1PC63 with BILLS
23 

•HR 5629 IH

1 by clause (iii), the interested third party 

2 shall identify that patent within 30 days of 

3 the date of issue of the patent, or the date 

4 of acquisition of the interest in the patent, 

5 as applicable. 

6 ‘‘(C) IDENTIFICATION OF BASIS FOR IN7 FRINGEMENT.—For any patent identified under 

8 clause (ii) or (iii) of subparagraph (A) or under 

9 clause (iii) or (iv) of subparagraph (B), the ref10 erence product sponsor or the interested third 

11 party, as applicable— 

12 ‘‘(i) shall explain in writing why the 

13 sponsor or the interested third party be14 lieves the relevant patent would be in15 fringed by the making, use, sale, or offer 

16 for sale within the United States, or im17 portation into the United States, of the 

18 biosimilar product or by a use of the bio19 similar product in treatment that is indi20 cated in the application; 

21 ‘‘(ii) may specify whether the relevant 

22 patent is available for licensing; and 

23 ‘‘(iii) shall specify the number and 

24 date of expiration of the relevant patent. 


rwilkins on PROD1PC63 with BILLS
24 

•HR 5629 IH

1 ‘‘(D) CERTIFICATION BY APPLICANT CON2 CERNING IDENTIFIED RELEVANT PATENTS.— 

3 Not later than 45 days after the date on which 

4 a patent is identified under clause (ii) or (iii) of 

5 subparagraph (A) or under clause (iii) or (iv) of 

6 subparagraph (B), the applicant shall send a 

7 written statement regarding each identified pat8 ent to the party that identified the patent. Such 

9 statement shall either— 

10 ‘‘(i) state that the applicant will not 

11 commence marketing of the biosimilar 

12 product and has requested the Secretary to 

13 not grant final approval of the application 

14 before the date of expiration of the noticed 

15 patent; or 

16 ‘‘(ii) provide a detailed written expla17 nation setting forth the reasons why the 

18 applicant believes— 

19 ‘‘(I) the making, use, sale, or 

20 offer for sale within the United 

21 States, or the importation into the 

22 United States, of the biosimilar prod23 uct, or the use of the biosimilar prod24 uct in a treatment indicated in the apVerDate Aug 31 2005 23:13 Mar 14, 2008 Jkt 069200 PO 00000 Frm 00024 Fmt 6652 Sfmt 6201 E:\BILLS\H5629.IH H5629

rwilkins on PROD1PC63 with BILLS
25 

•HR 5629 IH

1 plication, would not infringe the pat2 ent; or 

3 ‘‘(II) the patent is invalid or un4 enforceable. 

5 ‘‘(5) ACTION FOR INFRINGEMENT INVOLVING

6 REFERENCE PRODUCT SPONSOR.—If an action for 

7 infringement concerning a relevant patent identified 

8 by the reference product sponsor under clause (ii) or 

9 (iii) of paragraph (4)(A), or by an interested third 

10 party under clause (iii) or (iv) of paragraph (4)(B), 

11 is brought within 60 days of the date of receipt of 

12 a statement under paragraph (4)(D)(ii), and the 

13 court in which such action has been commenced de14 termines the patent is infringed prior to the date ap15 plicable under subsection (k)(7)(A), (k)(7)(D), or 

16 (k)(8) the Secretary shall make approval of the ap17 plication effective on the day after the date of expi18 ration of the patent that has been found to be in19 fringed. If more than one such patent is found to be 

20 infringed by the court, the approval of the applica21 tion shall be made effective on the day after the date 

22 that the last such patent expires. 

23 ‘‘(6) LIMITATIONS ON ACTIONS FOR DECLARA24 TORY JUDGMENT.—With respect to a patent that is 

25 the subject of an explanation under paragraph 


rwilkins on PROD1PC63 with BILLS
26 

•HR 5629 IH

1 (4)(D)(ii), no action for a declaratory judgment that 

2 the patent is invalid, unenforceable, or not infringed 

3 may be brought under section 2201 of title 28, 

4 United States Code, by an applicant prior to the 

5 date that is the later of— 

6 ‘‘(A) 3 years prior to the date applicable 

7 under subsection (k)(7)(A); or 

8 ‘‘(B) 120 days after such explanation has 

9 been provided.’’. 

10 (b) PRODUCTS PREVIOUSLY APPROVED UNDER SEC11 TION 505.— 

12 (1) REQUIREMENT TO FOLLOW SECTION 351.— 

13 Except as provided in paragraph (2), an application 

14 for a biological product shall be submitted under 

15 section 351 of the Public Health Service Act (42 

16 U.S.C. 262) (as amended by this Act). 

17 (2) EXCEPTION.—An application for a biologi18 cal product may be submitted under section 505 of 

19 the Federal Food, Drug, and Cosmetic Act (21 

20 U.S.C. 355) if— 

21 (A) such biological product is in a product 

22 class for which a biological product in such 

23 product class is the subject of an application 

24 approved under such section 505 not later than 

25 the date of enactment of this Act; and 


rwilkins on PROD1PC63 with BILLS
27 

•HR 5629 IH

1 (B) such application— 

2 (i) has been submitted to the Sec3 retary of Health and Human Services (re4 ferred to in this Act as the ‘‘Secretary’’) 

5 before the date of enactment of this Act; 

6 or 

7 (ii) is submitted to the Secretary not 

8 later than the date that is 10 years after 

9 the date of enactment of this Act. 

10 (3) LIMITATION.—Notwithstanding paragraph 

11 (2), an application for a biological product may not 

12 be submitted under section 505 of the Federal Food, 

13 Drug, and Cosmetic Act (21 U.S.C. 355) if there is 

14 another biological product approved under sub15 section (a) of section 351 of the Public Health Serv16 ice Act that could be a reference product with re17 spect to such application (within the meaning of 

18 such section 351) if such application were submitted 

19 under subsection (k) of such section 351. 

20 (4) DEEMED APPROVED UNDER SECTION 351.— 

21 An approved application for a biological product 

22 under section 505 of the Federal Food, Drug, and 

23 Cosmetic Act (21 U.S.C. 355) shall be deemed to be 

24 a license for the biological product under such secVerDate Aug 31 2005 23:13 Mar 14, 2008 Jkt 069200 PO 00000 Frm 00027 Fmt 6652 Sfmt 6201 E:\BILLS\H5629.IH H5629

rwilkins on PROD1PC63 with BILLS
28 

•HR 5629 IH

1 tion 351 on the date that is 10 years after the date 

2 of enactment of this Act. 

3 (5) DEFINITIONS.—For purposes of this sub4 section, the term ‘‘biological product’’ has the mean5 ing given such term under section 351 of the Public 

6 Health Service Act (42 U.S.C. 262) (as amended by 

7 this Act). 

8 SEC. 102. FEES RELATING TO BIOSIMILAR BIOLOGICAL 

9 PRODUCTS. 

10 Subparagraph (B) of section 735(1) of the Federal 

11 Food, Drug, and Cosmetic Act (21 U.S.C. 379g(1)) is 

12 amended by inserting ‘‘, including licensure of a biological 

13 product under section 351(k) of such Act’’ before the pe14 riod at the end. 

15 TITLE II—AMENDMENTS TO 

16 PATENT ACT 

17 SEC. 201. AMENDMENTS TO CERTAIN PATENT PROVISIONS. 

18 Section 271(e)(2) of title 35, United States Code is 

19 amended— 

20 (1) in subparagraph (A), by striking ‘‘or’’ after 

21 ‘‘patent’’; 

22 (2) in subparagraph (B), by adding ‘‘or’’ after 

23 the comma at the end; and 

24 (3) by inserting the following after subpara25 graph (B): 


rwilkins on PROD1PC63 with BILLS
29 

•HR 5629 IH

1 ‘‘(C) a statement under section 

2 351(l)(4)(D)(ii) of the Public Health Service 

3 Act,’’. 

Æ 


rwilkins on PROD1PC63 with BILLS